AUCTORES
Globalize your Research

Clinical Research Notes
Ashish Pandey *

Open Access

Review Article

Emergence of Bacteriocin-Producing Vancomycin-Resistant Enterococcus faecium in Nosocomial Settings

Ashish Pandey *, Gunjan Tomar

Daswani Dental College Affliated to Rajasthan University of Health Sciences, India.

***Corresponding Author:** Ashish Pandey. Daswani Dental College affliated to Rajasthan University of Health Sciences, India.

Received date: March 22, 2025; **Accepted date:** March 31, 2025; **Published date:** April 05, 2025

Citation: Ashish Pandey, Gunjan Tomar, (2025), Emergence of Bacteriocin-Producing Vancomycin-Resistant Enterococcus faecium in Nosocomial Settings, *J Clinical Research Notes*, 6(3); **DOI**:10.31579/2690-8816/165

Abstract

The rise of vancomycin-resistant Enterococcus faecium (VREfm) presents significant challenges in healthcare environments due to limited treatment options and increased mortality rates. Recent studies have identified VREfm strains capable of producing bacteriocins, antimicrobial peptides that inhibit closely related bacterial species. This review explores the genetic adaptations facilitating bacteriocin production in VREfm, their impact on strain dominance within hospital environments, and potential implications for therapeutic interventions.

Keywords: vancomycin-resistant enterococcus faecium; bacteriocins, nosocomial infections; antimicrobial resistance; genomic adaptations

Introduction

Enterococcus faecium is a Gram-positive bacterium that exists as a commensal organism in the human gastrointestinal tract but has evolved into a major nosocomial pathogen, particularly in immunocompromised patients [1]. The emergence of vancomycin-resistant Enterococcus faecium (VREfm) has significantly reduced treatment options and increased infection-related mortality [2]. The persistence and dominance of specific VREfm strains in healthcare environments require a deeper understanding of their adaptive mechanisms. One such mechanism is the acquisition of bacteriocin production, which may enhance strain survival and pathogenic potential [3].

Bacteriocin Production in VREfm

Bacteriocins are ribosomally synthesized antimicrobial peptides that enable bacterial species to inhibit competitors and establish dominance in a given niche [4]. In the case of VREfm, bacteriocin production is believed to provide a selective advantage by suppressing susceptible bacterial populations, facilitating colonization in hospitalized patients [5]. Recent genomic studies have identified bacteriocin-producing VREfm strains with distinct competitive properties that contribute to their persistence in nosocomial settings [6].

Genomic Insights

Whole-genome sequencing has revealed the presence of bacteriocin gene clusters in VREfm, suggesting horizontal gene transfer as a potential acquisition mechanism [7]. These gene clusters encode bacteriocins and their associated immunity proteins, which protect the producing strain from its own antimicrobial compounds [8]. Comparative genomic analyses indicate that these genetic elements are frequently linked to mobile genetic elements, further supporting their role in adaptation and spread within hospital environments [9].

Competitive Advantage in Nosocomial Environments

The ability to produce bacteriocins provides VREfm with a selective advantage in the competitive microbial environment of healthcare settings. Bacteriocin-mediated inhibition of other Enterococcus strains allows VREfm to dominate colonization sites, particularly in patients undergoing antibiotic therapy [10]. The widespread use of broad-spectrum antibiotics disrupts normal flora, creating an ecological vacuum that facilitates the expansion of resistant strains, including bacteriocin-producing VREfm [11].

Clinical Implications

The emergence of bacteriocin-producing VREfm has serious clinical implications. These strains demonstrate increased colonization rates and a higher likelihood of causing invasive infections, making infection control efforts more challenging [12]. Traditional decolonization strategies, such as probiotic administration or selective digestive decontamination, may be less effective against bacteriocin-producing strains due to their enhanced competitive capabilities [13].

Therapeutic Potential of Bacteriocins

Despite their role in VREfm pathogenicity, bacteriocins are being explored as potential antimicrobial agents against multidrug-resistant pathogens [14]. Their specificity and potency make them promising candidates for novel therapies, particularly in targeting resistant enterococcal strains. However, careful consideration is required to mitigate the risk of resistance

development and unintended ecological shifts in microbiota composition [15].

Conclusion

The acquisition of bacteriocin production by VREfm represents a significant evolutionary adaptation, contributing to its persistence and spread in hospital environments. Comprehensive genomic surveillance and innovative therapeutic strategies are essential to address the challenges posed by these adaptable pathogens. Future research should focus on understanding bacteriocin regulation, resistance mechanisms, and potential applications in antimicrobial therapy.

References

1. Leclercq R, Derlot E, Duval J, Courvalin P. (1988), Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. *N Engl J Med*, 157-61.
2. Cetinkaya Y, Falk P, Mayhall CG. (2000), Vancomycin-resistant enterococci. *Clin Microbiol Rev*, 686-707.
3. Gilmore MS, Lebreton F, van Schaik W. (2013), Genomic transition of enterococci from gut commensals to leading causes of multidrug-resistant hospital infection in the antibiotic era. *Curr Opin Microbiol*, 10-6.
4. Arias CA, Murray BE. (2012), The rise of the Enterococcus: beyond vancomycin resistance. *Nat Rev Microbiol*, 266-278.
5. Hegstad K, Mikalsen T, Coque TM, Werner G, Sundsfjord A. (2010), Mobile genetic elements and their contribution to the emergence of antimicrobial-resistant Enterococcus faecalis and Enterococcus faecium. *Clin Microbiol Infect*, 541-554.
6. Nes IF, Diep DB, Ike Y. (2014), Enterococcal bacteriocins and antimicrobial proteins that contribute to niche control. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: from commensals to leading causes of drug-resistant infection. Boston: *Massachusetts Eye and Ear Infirmary*.
7. van Tyne D, Martin MJ, Gilmore MS. (2013), Structure, function, and biology of the Enterococcus faecalis cytolysin. *Toxins (Basel)*, 895-911.
8. Lebreton F, Willems RJ, Gilmore MS. (2014), Enterococcus diversity, origins in nature, and gut colonization. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: from commensals to leading causes of drug-resistant infection. Boston: *Massachusetts Eye and Ear Infirmary*.
9. Murray BE. (1990), The life and times of the Enterococcus. *Clin Microbiol Rev*, 46-65.
10. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. (2011), Genetic basis for daptomycin resistance in Enterococcus faecalis. *Antimicrob Agents Chemother*, 3345-3356.
11. Willems RJ, van Schaik W. (2009), Transition of Enterococcus faecium from commensal organism to nosocomial pathogen. *Future Microbiol*, 1125-1135.
12. Arthur M, Courvalin P. (1993), Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother, 1563-1571.
13. Kristich CJ, Rice LB, Arias CA. (2014), Enterococcal infection—treatment and antibiotic resistance. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: from commensals to leading causes of drug-resistant infection. Boston: *Massachusetts Eye and Ear Infirmary*.
14. Cotter PD, Ross RP, Hill C. (2013), Bacteriocins—a viable alternative to antibiotics? *Nat Rev Microbiol*, 95-105.
15. Kommineni S, Bretl DJ, Lam V, Chakraborty R, Hayward M, et al. (2015), Bacteriocin production augments colonization resistance against the human pathogen Clostridium difficile. *Nat Commun*, 73-84.

DOI:10.31579/ 2690-8816/165